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Abstract 
We investigated red blood cell (RBC) PUFA profiles, and the predictive value of RBC 
EPA content for tumour EPA exposure and clinical outcomes, in the EMT study, a 
randomised trial of EPA in patients awaiting colorectal cancer (CRC) liver metastasis 
surgery (A.J. Cockbain et al, 2014). There was a significant increase in RBC EPA in 
the EPA group (n=43; median intervention 30 days; mean absolute 1.26 [±0.14]% 
increase; P<0.001), but not in the placebo arm (n=45). EPA incorporation varied 
widely in EPA users and was not explained by treatment duration or compliance. 
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There was OLWWOHHYLGHQFHRIµFRQWDPLQDWLRQ¶ in the placebo group. The EPA level 
predicted tumour EPA content (r=0.36; P=0.03). Participants with post-treatment 
(3$Q ) had improved OS compared with EPA <1.22% (n=29; HR 
0.42[95%CI 0.16-0.95]). RBC EPA content should be evaluated as a biomarker of 
tumour exposure and clinical outcomes in future EPA trials in CRC patients. 
Keywords: colorectal cancer; eicosapentaenoic acid; omega-3 polyunsaturated fatty 
acid 
Introduction 
The clinical efficacy of omega-3 polyunsaturated fatty acids (PUFAs1) has been 
tested in randomised, double-blind, placebo-controlled trials in multiple adult 
healthcare settings including studies of cardiovascular disease [1], inflammatory 
bowel disease [2], non-alcoholic fatty liver disease [3] and cancer [4-5]. However, 
despite the widespread availability of mass spectrometric techniques for measuring 
PUFAs, only a minority of clinical omega-3 PUFA studies with a primary or 
secondary clinical endpoint have reported target organ PUFA incorporation and/or 
individual blood PUFA profiles [3,5-6], with which to interpret PUFA µbioavailability¶a 
term usually used in omega-3 PUFA studies to indicate the tissue or blood level of 
omega-3 PUFAs)FRPSOLDQFHDQGµFRQWDPLQDWLRQ¶E\H[FHVVµRZQXVH¶RIWKH
intervention or dietary omega-3 PUFA intake, the latter being a particular threat to 
correct interpretation of trial data and the statistical power of a trial for any substance 
WKDWLVHDVLO\DYDLODEOHµRYHUWKHFRXQWHU¶ or as a dietary constituent [7]. 
We have previously reported the results of a Phase II randomised, double-blind, 
placebo-controlled trial of 99% pure eicosapentaenoic acid (EPA) in the free fatty 
                                                          
1
 Abbreviations: AA, arachidonic acid; CRC, colorectal cancer; DHA, docosahexaenoic acid; DPA, 
docosapentaenoic acid; EPA, eicosapentaenoic acid; FFA, free fatty acid; LC-MS/MS, liquid 
chromatography-tandem mass spectrometry; LM, liver metastasis; OS, overall survival; PUFA, 
polyunsaturated fatty acid; RBC, red blood cell 
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acid (FFA) form in patients undergoing liver resection surgery for colorectal cancer 
liver metastasis (CRCLM), called the EMT study [8]. ,QWKLVµZLQGRZRIRSSRUWXQLW\¶
trial, gastro-resistant EPA-FFA or identical placebo capsules were taken for a 
variable amount of time between the decision to undergo surgery and liver resection, 
at which time the trial intervention was stopped. We demonstrated that EPA-FFA 2 g 
daily before liver surgery was safe and well-tolerated. Analysis of resected CRCLM 
tissue confirmed that orally administered EPA was incorporated into target tumour 
tissue and was associated with a reduction in tumour vascularity as measured by 
CD31-positive microvessel density [8]. An intriguing preliminary observation was that 
EPA may provide prolonged overall survival (OS) and disease-free survival (DFS) 
benefit after treatment cessation following liver surgery [8].  
A methodological limitation of the trial was that we were only able to obtain 
CRCLM tissue at surgery after EPA treatment, thus excluding any longitudinal 
analysis of PUFA incorporation and µZDVKRXW¶LQWDUJHt CRCLM tissue. However, we 
obtained blood from participants at randomisation (baseline), the day prior to liver 
surgery (post-treatment), and several weeks after surgery (µwashout¶). Red blood cell 
(RBC) membrane omega-3 PUFA content is widely accepted as the best surrogate 
biomarker of omega-3 PUFA content in other tissues such as the heart and liver [9-
10].  
Therefore, we analysed the RBC membrane omega-3 PUFA content at baseline, 
post-treatment and at follow-up after surgery in the EMT study, allowing us to 
interpret individual PUFA content profiles in both active (EPA) and placebo groups, 
correlate RBC PUFA content with CRCLM levels, and explore the use of RBC EPA 
content as a predictor of survival in patients who have undergone liver surgery for 
CRCLM. 
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Methods 
2.1 The EMT study 
This Phase II randomised, double-blind, placebo-controlled trial (ClinicalTrials.gov 
NCT01070355) has been described in detail previously [8]. Participants were 
randomised to EPA-FFA 2 g taken as two gastro-resistant capsules twice daily with 
food for a median (range) duration of 30 (12-65) days (n=43) or placebo (capric and 
caprylic acid triglycerides) capsules for a median 26 (15-73) days (n=45). Blood 
samples were obtained at randomisation (baseline; n=87), the day prior to liver 
surgery (post-treatment; n=79), and approximately six weeks (EPA median [range] 
47 [16-110] days; placebo 44 [21-68]) after surgery (washout; n=70). Participants 
were stratified by prior fish oil supplement use and/or high dietary (> 2 oily fish 
portions per week) omega-3 PUFA intake. We have previously reported that dietary 
omega-3 PUFA intake did not change significantly in either treatment group during 
the trial as measured by a modified validated food frequency questionnaire [8]. 
Percentage compliance with capsules was calculated from the difference in actual 
and expected capsules use based on a capsule count at the trial visit immediately 
prior to surgery. Participants were all given capsules in slight excess of requirements 
and were admitted for surgery at different times after randomisation. A lower than 
H[SHFWHGFDSVXOHFRXQWEHIRUHVXUJHU\LVH[SUHVVHGDVµFRPSOLDQFH¶!   
2.2 PUFA measurement 
Blood was collected in two EDTA-coated Vacuette® tubes on ice and the RBC 
slurry was obtained after centrifugation at 700 g for 10 minutes at 4oC within three 
hours of venepuncture. Isolated RBCs were stored at -80oC until fatty acid 
extraction. 
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Fatty acids were extracted from erythrocytes using the following method adapted 
from the protocol first published by Rose et al [11]. Isolated erythrocytes were 
washed three times with 5 volumes of 0.89% Sodium chloride (NaCl), before 
transferring 50 ȝL into a 1.7 mL Eppendorf® tube. Erythrocytes were mixed with 50 
ȝOGLVWLOOHGZDWHUDQGDOORZHGWRVWDQGIRUPLQutesȝL isopropanol was added 
VORZO\ZLWKPL[LQJDQGIROORZLQJLQFXEDWLRQIRUKRXUDWURRPWHPSHUDWXUHȝL 
chloroform was added. After a further 1 hour incubation, samples were centrifuged at 
10 000 g for 5 minutes. The supernatant was then evaporated in a rotary evaporator 
DQGUHFRQVWLWXWHGLQȝL acetonitrile. Hydrolysis was performed with the addition 
RIȝL 5M HCl IROORZHGE\LQFXEDWLRQDW&IRUKRXUȝL of 5M NaOH was 
then DGGHGDQGWKHVDPSOHPL[HGEHIRUHDGGLWLRQRIȝOFKORURIRUP7KHVDPSOH
was left to stand for 5 min to allow the solvent layers to separate, before taking the 
WRSȝODQGHYDSRUating in a rotary evaporator. Extracted fatty acids were then 
UHFRQVWLWXWHGLQȝL methanol prior to derivatisation. 
We measured FAs by liquid chromatography-tandem mass spectrometry (LC-
MS/MS) [12]. The following FAs were measured with the relative level of each PUFA 
expressed as the % of the total FA content: alpha-linolenic acid (C18:3Z3), EPA 
(C20:5Z3), docosapentaenoic acid (DPA; C22:5Z3), docosahexaenoic acid (DHA; 
C22:6Z3), linoleic acid (C18:2Z6), arachidonic acid (AA;C20:4Z6), palmitic acid 
(C16:0), stearic acid (C18:0), oleic acid (C18:1Z9). Tumour tissue PUFA content was 
measured previously and has been reported in the EMT study publication [8].  
2.3 Statistical analysis 
PUFA data are quoted as the mean (± standard error of the mean [SEM]) relative 
(%) amount of each PUFA compared with the total fatty acid content measured by 
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LC-MS/MS. Individual absolute and fold changes in PUFA content over time were 
compared using the one-sample T test. Pairwise differences in relative PUFA 
content over time were analysed by the paired-sample T test. Data that were not 
normally distributed were analysed by the Mann Whitney U test. 3HDUVRQ¶V
correlation test was used to explore the relationship between continuous variables 
including RBC and tumour % PUFA content. Comparison of OS in trial participants 
with a % RBC EPA level or 1.22 (the lowest post-treatment % EPA level in the EPA 
group) was performed using Kaplan-Meier survival analysis and log rank test. 
Results 
3.1 Time course of RBC EPA incorporation DQGµZDVKRXW¶LQ&5&/0SDWLHQWV 
Baseline % RBC PUFA levels in patients with CRCLM are displayed in Figure 1. 
There was a rise in RBC EPA content in patients randomised to EPA-FFA treatment 
with a mean absolute 1.26 (±0.14 [SEM])% increase during treatment (P<0.001, one-
sample T test; Figure 1A and 2A), which was not observed in the placebo group (-
0.03±0.04%; Figure 1A and Figure 2B). This equated to a mean 2.40 (±0.16)-fold 
increase in RBC EPA content during EPA treatment (placebo 1.02±0.04 fold 
change). There was also a smaller increase in RBC DPA content (mean 0.60±0.18 
[SEM] absolute increase; P<0.05; Figure 1B and 2C). A small, but statistically 
significant, reduction in relative DHA content in RBC membranes (mean absolute 
0.31±0.24% reduction) was also seen following EPA treatment (Figure 1C). There 
was a concurrent, statistically significant decrease in omega-6 PUFA AA content 
(mean absolute 1.31±0.57% reduction) in those individuals receiving EPA (P<0.05; 
Figure 1D and Figure 2G). The EPA/AA ratio is widely quoted as a predictive 
biomarker of omega-3 PUFA activity, particularly in cardiology studies [13]. There 
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was a mean absolute increase in EPA/AA ratio of 0.12 (SEM 0.01) at the end of the 
intervention period in those allocated to EPA with RBC EPA/AA ratio values at the 
end of the intervention period ranging between 0.09 and 0.37 (mean 0.21). 
There was no overall change in % RBC content of any PUFA in the placebo group 
(Figure 1 and Figure 2B, D, F and H). For each PUFA, there was significant, but 
incomplete, reversal of the changes in PUFA content related to EPA treatment 
during the post-LQWHUYHQWLRQµZDVKRXW¶SHULRG)LJXUHDQG)LJXUH$&(DQG*$
persistent, small elevation in RBC EPA and DPA content was observed at six weeks 
after cessation of EPA treatment (Figure 1A and B), along with reduced AA content 
(Figure 1D).  
Individual RBC PUFA content profiles varied significantly between individuals in 
both EPA and placebo groups (Figure 2A-H). Previous fish oil supplement users 
(who were required to stop this for the duration of the trial) and those with high 
dietary omega-3 PUFA intake (n=23) had a significantly higher baseline % RBC EPA 
content (1.39±0.15%WKDQSDUWLFLSDQWVµQDwYH¶WRERWK0.97±0.04%; n=64; P=0.003). 
The four participants in the placebo arm with the highest baseline % EPA content (all 
>2%) were all fish oil supplement users or those classified as having a high dietary 
omega-3 PUFA intake (Figure 2B). All these individuals that supplied blood samples 
after baseline displayed a reduction in RBC EPA content during the intervention 
period consistent with adherence to the protocol, which demanded cessation of 
existing omega-3 PUFA supplement use (Figure 2B). Thirty-three out of 36 (92%) 
participants, who received EPA and for whom data from all three time-points were 
available, demonstrated an increase in RBC EPA content during the intervention 
period, which then reduced after treatment cessation (Figure 2A). This suggests 
excellent compliance with trial treatment. However, the magnitude of the EPA 
8 
 
 
 
µUHVSRQVH¶YDried widely with only 20 individuals displaying a %EPA RBC content of 
greater than 2% (Figure 2A). 
There was no statistically significant correlation between the % RBC EPA content 
at the end of the intervention period and the duration of EPA treatment (r=0.25; 
P=0.12; Figure 3A). The post-treatment absolute EPA level attained in females 
(mean 2.68±0.23%; n=16) was greater than in male participants (mean absolute 
2.07±0.0.14%; n=23) in the EPA group (P=0.02). There was no difference in 
baseline or post-intervention RBC PUFA levels in concurrent aspirin users (n=9) 
compared with non-users in the EPA group (data not shown). µ&RPSOLDQFH¶ZLWK
FDSVXOHVPHDVXUHGE\µSLOOFRXQWLQJ¶LQERWKDFWLYHDQGSODFHERJURXSVZDVJRRG
and has been reported previously [8]. Mean compliance in the EPA group was 
89.5±2.9% (range 40.9-116.7). There was no significant correlation between % 
compliance and post-treatment % RBC EPA level (r=0.09; P=0.59) in EPA users. 
Multivariate linear regression inputting gender, treatment duration and compliance 
confirmed that gender alone (beta -0.35, P=0.039) remained the only significant 
predictor of post-treatment RBC EPA level in the EPA treatment group.      
Of note, the individual with the largest increase in RBC EPA content (gold 
symbols and line) also demonstrated a marked increase in DPA and DHA, but also 
AA (Figure 2A, C, E and G). The most likely explanation is µFRQWDPLQDWLRQ¶by 
concurrent use of a mixed omega-3 and omega-6 PUFA supplement, many of which 
are available commercially. Only one individual allocated to placebo demonstrated 
an increase in RBC EPA content over time (yellow crosses and line), also suggesting 
SRVVLEOHµFRQWDPLQDWLRQ¶E\µRZQ¶RPHJD-3 PUFA use.       
3.2 Relative RBC EPA content predicts the CRCLM tissue EPA level 
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Measurement of the % RBC EPA content the day before surgery allowed a 
pairwise comparison of RBC EPA content and the corresponding tumour EPA level 
at CRCLM resection (Figure 3B). There was a significant correlation between the % 
RBC EPA level just prior to surgery and the CRCLM EPA content in those 
participants who received EPA (r=0.35, P=0.03) and placebo (r=0.72; P<0.001: 
Figure 3B). Interestingly, those individuals in the placebo group with relatively high % 
RBC EPA content, as a consequence of prior omega-3 PUFA use or high dietary 
intake, had a correspondingly high tumour EPA content (Figure 3B).  
3.3 RBC EPA incorporation and long-term clinical outcomes 
Long-term clinical outcomes were an exploratory end-point in the Phase II EMT 
study [8]. A preliminary finding was that those patients who were randomised to EPA 
treatment had OS benefit compared with placebo, although the difference was not 
statistically significant in this small randomised trial [8]. On the basis that the lowest 
post-treatment % RBC EPA level attained in the EPA group was 1.22%, which is 
higher than all the respective placebo group values except for 10 individuals (6 of 
whom had high baseline levels due to significant prior dietary or supplement omega-
3 PUFA exposure), we compared OS in individuals with a post-treatment % RBC 
EPA content of 1.22% with those with a post-treatment RBC EPA content of 
<1.22%, regardless of treatment allocation in the trial.  Participants with a post-
WUHDWPHQW5%&(3$FRQWHQWRI2% (n=49) demonstrated improved OS 
compared with those with a RBC EPA level <1.22% (n=29; Figure 4). The hazard 
ratio was 0.42 (95% confidence interval 0.16-0.95) with a log rank P value of 0.04.  
     
4. Discussion 
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This is the first time that individual RBC and tumour PUFA content values have 
been analysed together in a randomised, placebo-controlled trial of an omega-3 
PUFA in cancer patients. We measured % RBC omega-3 PUFA content as the 
biomarker of choice, with least within-subject variability, for assessment of omega-3 
38)$µELRDYDLODELOLW\¶ in a clinical study lasting several weeks [9-10].  
We report that RBC EPA incorporation predicts CRCLM EPA content and 
therefore has potential as a surrogate biomarker of short-term target organ EPA 
exposure, at least in CRCLM. Consistent with this finding, RBC and cardiac/breast 
tissue EPA content correlate strongly after omega-3 PUFA supplementation in 
humans [14-16], and RBC omega-3 PUFA levels correlate with omega-3 PUFA 
content in multiple mouse and rat tissues after dietary supplementation [17-18].  
Baseline and post-treatment RBC PUFA levels in EMT study participants were 
similar to those reported previously in studies of omega-3 PUFA supplementation in 
healthy volunteers [13, 19], women with breast hyperplasia [20-21] and in patients 
with lung cancer [22]. In particular, post-treatment % RBC EPA values were similar 
to those observed in an eight-week study of exactly the same EPA-FFA formulation 
and dose in healthy volunteers and inflammatory bowel disease patients [23]. In 
keeping with previous studies of pure EPA treatment, there was some evidence of 
elongation of EPA to DPA leading to a small, statistically insignificant increase in 
RBC DPA incorporation [8, 23-24]. However, there was no evidence of DHA 
incorporation in RBC membranes, with an actual small reduction in % DHA content 
in EPA users, unlike the previous study with EPA-FFA [23]. This may be explained 
by the shorter duration of EPA supplementation in the EMT study, which may lead to 
displacement of membrane DHA by excess EPA-FFA, prior to de novo synthesis of 
DHA from EPA. Alternatively, it is understood that excess EPA may saturate the 
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second ELOVL2 elongase reaction necessary for DPA to DHA conversion, which 
could lead to a reduced relative DHA content [24]. 
The literature on omega-3 PUFA supplementation in healthy volunteers and 
patient groups would suggest that omega-3 PUFA incorporation is associated with a 
reciprocal reduction in membrane content of the omega-6 PUFA counterpart to EPA, 
AA [19-21, 23, 25-26]. We also observed this phenomenon in the EMT study, despite 
the relatively short duration of EPA supplementation.  
Overall, there was consistent and uniform, but incomplete, (3$µZDVKRXW¶RYHUthe 
relatively short time period between surgery and post-operative follow-up mandated 
in the trial. Longer-term follow-up would have been required in order to confirm the 
return of the PUFA profile in RBCs to that observed pre-intervention. µ:DVKRXW¶
kinetics were not dependent on the prior degree of RBC incorporation or duration of 
EPA treatment and are similar (in these CRC patients) to the decay in RBC EPA 
content observed in at least three healthy volunteer studies, in which peak RBC EPA 
content was similar to that seen in the EMT study [13, 19, 27], as well as two more 
recent studies of pre- and post-menopausal women [20-21].            
Individual omega-3 PUFA profiles allowed us to investigate inter-patient variability 
in EPA incorporation in CRC patients. There was significant heterogeneity in the 
increase in EPA content of RBC membranes in response to EPA treatment, which 
has previously been noted in intervention studies of daily supplementation with 
combined EPA and DHA formulations (measured as the omega-3 index) in 
atherosclerotic patients [28-29], but not cancer patients. This is in contrast to the 
more uniform incorporation of EPA into RBC membranes observed in the healthy 
volunteer study of EPA-FFA by Scaioli et al [23]. A similar degree of inter-individual 
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variability in plasma phospholipid DHA level was observed in a DHA intervention 
study in breast cancer patients [30].    
There was a small but statistically significant difference in RBC EPA incorporation 
in women compared with men in the EPA group, which remained even after 
adjustment for treatment duration and compliance. A meta-analysis of gender 
differences in omega-3 PUFA levels in RBC membranes has previously reported a 
significantly higher DHA, but not EPA, content in RBCs in women compared with 
men [29]. However, a previous supplementation study, which undertook a gender-
specific analysis, reported on gender difference in omega-3 index [31].         
Individual omega-3 PUFA profiles also highlighted possible cases of 
µFRQWDPLQDWLRQ¶E\SULRURUFRQFXUUHQWomega-3 PUFA intake separate from the 
Investigational Medicinal Product. This was most easily observed in several 
instances in the placebo arm, in which a concurrent increase in DHA (but not DPA) 
suggested use of a combined EPA/DHA omega-3 PUFA formulation in addition to 
SODFHERµ&RQWDPLQDWLRQ¶E\H[WUDRPHJD-3 PUFA use may also explain the high 
(3$DQG'+$µRXWOLHU¶LQWKH(3$DUPRIWKHWULDODOWKRXJKWKHFRQFXUUHQWKLJK5%&
DPA content may signal that this individual was, in fact, capable of extremely 
efficient EPA-DPA-DHA conversion. There is increasing understanding of the genetic 
basis of inter-individual variability in omega-3 PUFA interconversion, underlying 
which genetic polymorphisms in the FADS1-FADS2 cluster and ELOVL2/5 genes 
modulate desaturase and elongase activities [32]. 
Placebo group contamination is an ever-present risk in a randomised trial of any 
LQWHUYHQWLRQDYDLODEOHµRYHUWKHFRXQWHU¶ [33], particularly when fish oil use is so 
widespread (7.8% of US adults in 2012 [34]). However, contamination by omega-3 
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PUFA use in the placebo arm (suggested by an increase in omega-3 PUFA RBC 
content during the intervention period) appeared relatively low, occurring in perhaps 
4 (9%) of 45 individuals allocated to placebo, and possibly in a single case (2%) in 
the EPA group. Therefore, contamination by additional omega-3 PUFA use is 
unlikely to have affected significantly the laboratory and clinical endpoints of the EMT 
study.      
There has been only one previous randomised omega-3 PUFA intervention trial in 
cancer patients that has reported individual omega-3 PUFA levels during treatment 
[6] and none that have included an analysis of omega-38)$µZDVKRXW¶DIWHU
cessation of omega-3 PUFA supplementation. Van der Meij et al described variability 
in plasma phospholipid EPA levels after double-blind intervention for 5 weeks with a 
daily supplement containing 2 g EPA and 0.9 g DHA or isocaloric control in patients 
with non-small cell lung cancer [6]. These authors obtained similar individual EPA 
SURILOHVWRWKH(07VWXG\ZLWKDQXPEHURIµQRQ-responders¶LQWKHLQWHUYHQWLRQDUP
DQGFRQYHUVHO\VRPHLQGLYLGXDOVZLWKKLJKEDVHOLQH(3$YDOXHVRUDQµ(3$
UHVSRQVH¶LQWKHFRQWURODUPRIWKHVWXG\[6]. We suggest that contamination is likely 
to occur in all trials of omega-3 PUFA supplements with individual randomisation and 
can be, at least partly, adjusted for by analysis by absolute or relative change in RBC 
omega-3 PUFA levels. 
To the best of our knowledge, survival analysis based on EPA incorporation in 
RBCs, as a surrogate biomarker of tumour EPA exposure, has not been reported 
previously. Despite the relatively small sample size of the EMT trial, there was a 
statistically significant difference between individuals dichotomised on the basis of 
the RBC EPA content at the end of the intervention period (irrespective of the trial 
treatment allocation). Effectively, this moved those individuals in the placebo group 
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with relatively high RBC EPA levels (explained mainly by high dietary marine omega-
3 PUFA intake or prior supplement use) into the active (EPA) group. A 
methodological weakness of this approach is the rather arbitrary cut-off value, which, 
in this case, was selected as the lowest relative RBC EPA level in an µEPA-
responder¶LQFUHDVHLQ(3$FRQWHQWGXULQJLQWHUYHQWLRQDQGWKHQUHGXFWLRQGXULQJ
µZDVKRXW¶ However, the EPA value used (1.22%) was similar to equivalent values 
used in previous cohort and case-control studies of the association between omega-
3 PUFA levels and CRC risk [35], in particular the study of Cottet et al which 
measured RBC EPA content [36]. Moreover, in the absence of a widely recognised, 
standardized method for measurement of RBC fatty acid content, we used a LC-
MS/MS method, thus restricting future comparison with other studies.     
We suggest that a so-FDOOHGµcontamination-adjusted¶ secondary analysis [7] 
should be undertaken in future randomised, double-blind trials of omega-3 PUFAs in 
which PUFA levels are measured. Such an approach was recently taken in the 
WELCOME study of non-alcoholic fatty liver disease patients, in which placebo- and 
active-group contamination occurred to a similar extent to the EMT study [3]. 
In conclusion, we report significant variability in RBC omega-3 PUFA profiles 
during a randomised trial of EPA in patients with CRCLM awaiting liver resection. 
There was evidence of FRQWDPLQDWLRQE\µRZQXVH¶RPHJD-3 PUFA in only a small 
proportion of participants. There was a significant correlation between the RBC EPA 
content and CRC liver metastasis EPA level measured within 24 hours of each other 
in this EPA intervention trial, implying that the RBC omega-3 PUFA content may 
reflect tumour omega-3 PUFA exposure, at least in CRCLMs. 
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A fascinating preliminary observation is that OS analysis based on post-
intervention RBC EPA content, rather than treatment allocation, suggested OS 
benefit in those individuals with a high relative EPA level. This finding adds further to 
the rationale for a phase III omega-3 PUFA intervention trial in CRCLM patients. 
Consistent with the hypothesis that EPA therapy may provide survival benefit in this 
group of patients, Song et al have recently reported that higher marine omega-3 
PUFA intake is associated with reduced post-diagnosis CRC mortality in two US 
cohort studies [37].  
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Figure 1. Baseline % RBC PUFA level and absolute difference in % RBC PUFA 
level between baseline and post-treatment or after surgery (washout). In each 
case (A-D), the left y axis is the baseline % RBC PUFA value and the right y axis is 
the absolute difference between the post-WUHDWPHQWYDOXHRUµZDVKRXW¶SRVW-operative 
value and baseline % level. Columns (baseline % values) and symbols (absolute 
difference in % value from baseline) denote the mean for EPA and placebo (Plac.) 
groups. Error bars denote the standard error of the mean.*P<0.05, **P<0.001; one-
sample t test. 
Figure 2. Individual % RBC PUFA profiles for individuals randomised to either 
EPA (A, C, E, G) or placebo (B, D, F, H). Different coloured lines join data points for 
all individuals.  
Figure 3. Relationship between the % RBC EPA level at the end of the trial 
intervention and either treatment duration (A) or tumour EPA content at 
surgery (B). Open symbols denote individual data from the placebo group and filled 
symbols denote EPA group data. B) 7KHGDVKHGOLQHGHQRWHVWKH5%&(3$µFXW-
RII¶1.22 for survival analysis). Arrows denote examples of individual patient data in 
prior omega-3 PUFA supplement users allocated to placebo, who had high tumour % 
EPA content.  
Figure 4. Overall survival analysis of CRCLM patients stratified on the basis of 
post-treatment % RBC EPA level, not treatment allocation. The cut-off of 1.22% 
ZDVEDVHGRQWKHORZHVWYDOXHLQGLFDWLYHRIDQ(3$µUHVSRQVH¶HYLGHQFHGE\DQ
increase in EPA level from baseline to post-treatment measurement and then 
µZDVKRXW¶LQWKH(3$JURXS. Vertical ticks denote censored cases. Solid line denotes 
HYHQWVLQ(3$µincorporatoUV¶SRVW-treatment RBC % EPA level 1.22%. Dashed line 
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GHQRWHVHYHQWVLQ(3$µQRQ- incorporators¶SRVW-treatment RBC % EPA level 
<1.22%.  Log rank P=0.04.     
 
 
 
Highlights 
x Individual red blood cell (RBC) and tumour polyunsaturated fatty acid (PUFA) 
levels have not previously been reported in a randomised trial of omega-3 
PUFA supplementation in cancer patients.  
x Our data highlight the high inter-patient variability in eicosapentaenoic acid 
(EPA) incorporation in cells that occurs during oral dosing in colorectal cancer 
(CRC) patients.  
x Importantly, we demonstrate, for the first time, that the RBC EPA level 
predicts CRC liver metastasis EPA exposure during EPA treatment, 
suggesting a role for RBC PUFA analysis as a non-invasive biomarker of 
tumour EPA exposure in future phase III trials.  
x A fascinating preliminary observation is that RBC EPA content, irrespective of 
randomisation to either EPA or placebo, was related to post-trial overall 
survival.  
x Future trials of omega-3 PUFA supplementation should incorporate secondary 
analysis of blood omega-3 PUFA levels as a predictor of clinical outcomes, 
especially as background dietary intake of omega-3 PUFA can vary 
significantly and ZLGHVSUHDGXVHRIµRZQ¶RPHJD-38)$VPD\µFRQWDPLQDWH¶
the placebo group. 
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